

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:sssptal653hxp
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files
NEWS 3 Feb 06 Engineering Information Encompass files have new names
NEWS 4 Feb 16 TOXLINE no longer being updated
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA

NEWS EXPRESS April 18 CURRENT WINDOWS VERSION IS V6.0,
CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
AND CURRENT DISCOVER FILE IS DATED 04/06
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:57:47 ON 27 APR 2001

=> file medline, biosis, dgene, uspat, hcaplus, embase, scisearch, biotechabs, biotechds, uspat, wpids, japio, jicst, fsta, frosti, cen, ceaba

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 0.30 | 0.30 |

FILE 'MEDLINE' ENTERED AT 12:58:54 ON 27 APR 2001

FILE 'BIOSIS' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'DGENE' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'USPATFULL' ENTERED AT 12:58:54 ON 27 APR 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'HCAPLUS' ENTERED AT 12:58:54 ON 27 APR 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 Institute for Scientific Information (ISI) (R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'WPIDS' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'JAPIO' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

FILE 'JICST-EPLUS' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 Japan Science and Technology Corporation (JST)

FILE 'FSTA' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 International Food Information Service

FILE 'FROSTI' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 Leatherhead Food Research Association

FILE 'CEN' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CEABA-VTB' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (c) 2001 DECHEMA eV

=> s multidrug resistance

L1 40264 MULTIDRUG RESISTANCE

=> s annexin

L2 12885 ANNEXIN

=> s l2 and type one

9 FILES SEARCHED...
L3 0 L2 AND TYPE ONE

=> s l2 and l1

L4 81 L2 AND L1

=> s l4 and p-40

L5 13 L4 AND P-40

=> s l5 and method

L6 10 L5 AND METHOD

=> d l6 ti abs ibib tot

L6 ANSWER 1 OF 10 USPATFULL

TI Antibodies to a **multidrug resistance** protein

AB A novel protein associated with **multidrug resistance** in living cells and capable of conferring **multidrug resistance** on a cell is disclosed. Nucleic acids encoding the novel **multidrug resistance** protein are also disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Antibodies which bind the novel **multidrug resistance** protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:61437 USPATFULL

TITLE: Antibodies to a **multidrug resistance** protein

INVENTOR(S): Deeley, Roger G., Kingston, Canada
Cole, Susan P. C., Kingston, Canada

PATENT ASSIGNEE(S): Queen's University at Kingston, Kingston, Canada
(non-U.S. corporation)

| | NUMBER | DATE |
|-----------------------|--|--------------|
| PATENT INFORMATION: | US 6063621 | 20000516 |
| APPLICATION INFO.: | US 1995-407207 | 19950320 (8) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1993-141893, filed on 26 Oct 1993, now patented, Pat. No. US 5489519 | |

which

is a continuation-in-part of Ser. No. US 1993-29340, filed on 8 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-966923, filed on 27 Oct 1992, now abandoned

DOCUMENT TYPE: Utility

PRIMARY EXAMINER: Huff, Sheela

ASSISTANT EXAMINER: Reeves, Julie E

LEGAL REPRESENTATIVE: Steeg, Carol Miernicki; Kara, Catherine J.; DeConti, Jr., Giulio A.

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 23 Drawing Figure(s); 21 Drawing Page(s)

LINE COUNT: 3685

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 10 USPATFULL

TI **Multidrug resistance** proteins

AB A novel protein associated with **multidrug resistance** in living cells and capable of conferring **multidrug resistance** on a cell is disclosed. Nucleic acids encoding the novel **multidrug resistance** protein are also disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Antibodies which bind the novel **multidrug resistance** protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:18558 USPATFULL

TITLE: **Multidrug resistance** proteins

INVENTOR(S): Deeley, Roger G., Kingston, Canada
PATENT ASSIGNEE(S): Cole, Susan P. C., Kingston, Canada
Queen's University at Kingston, Kingston, Canada
(non-U.S. corporation)

| | NUMBER | DATE |
|--|---|--------------|
| PATENT INFORMATION: | US 6025473 | 20000215 |
| APPLICATION INFO.: | US 1995-461384 | 19950605 (8) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1995-407207, filed on 20 Mar 1995 which is a continuation-in-part of Ser. No. US 1993-141893, filed on 26 Oct 1993, now patented, | |
| | Pat. No. US 5489519 which is a continuation-in-part of Ser. No. US 1993-29340, filed on 8 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-966923, filed on 27 Oct 1992, now abandoned | |
| DOCUMENT TYPE: | Utility | |
| PRIMARY EXAMINER: | Burke, Julie | |
| LEGAL REPRESENTATIVE: | Steeg, Carol Miernicki; Kara, Catherine J.; DeConti, Jr., Giulio A. | |
| NUMBER OF CLAIMS: | 19 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 23 Drawing Figure(s); 21 Drawing Page(s) | |
| LINE COUNT: | 4915 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | |

L6 ANSWER 3 OF 10 USPATFULL
TI Methods for identifying chemosensitizers
AB A novel protein associated with **multidrug resistance** in living cells and capable of conferring **multidrug resistance** on a cell is disclosed. Nucleic acids encoding the novel **multidrug resistance** protein are also disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Antibodies which bind the novel **multidrug resistance** protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:163419 USPATFULL
TITLE: Methods for identifying chemosensitizers
INVENTOR(S): Deeley, Roger G., Kingston, Canada
Cole, Susan P.C., Kingston, Canada
PATENT ASSIGNEE(S): Queen's University at Kingston, Kingston, Canada
(non-U.S. corporation)

| | NUMBER | DATE |
|-----------------------|---|--------------|
| PATENT INFORMATION: | US 6001563 | 19991214 |
| APPLICATION INFO.: | US 1995-463179 | 19950605 (8) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1995-407207, filed on 20 Mar 1995 which is a continuation-in-part of Ser. No. US 1993-141893, filed on 26 Oct 1993, now patented, | |
| | Pat. No. US 5489519, issued on 6 Feb 1996 which is a continuation-in-part of Ser. No. US 1993-29340, filed on 8 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-966923, filed on 27 Oct 1992, now abandoned | |
| DOCUMENT TYPE: | Utility | |
| PRIMARY EXAMINER: | Stanton, Brian R. | |

ASSISTANT EXAMINER: Clark, Deborah J. R.
LEGAL REPRESENTATIVE: Steeg, Carol Miernicki; Kara, Catherine J.; DeConti, Jr., Giulio A.

NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1,7
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 4885
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 10 USPATFULL

TI Methods for conferring **multidrug resistance** on a cell

AB A novel protein associated with **multidrug resistance** in living cells and capable of conferring **multidrug resistance** on a cell is disclosed. Nucleic acids encoding the novel **multidrug resistance** protein are also disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Antibodies which bind the novel **multidrug resistance** protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:43471 USPATFULL
TITLE: Methods for conferring **multidrug resistance** on a cell
INVENTOR(S): Deeley, Roger G., Kingston, Canada
Cole, Susan P. C., Kingston, Canada
PATENT ASSIGNEE(S): Queen's University at Kingston, Kingston, Canada
(non-U.S. corporation)

| | NUMBER | DATE |
|-----------------------|---|--------------|
| PATENT INFORMATION: | US 5891724 | 19990406 |
| APPLICATION INFO.: | US 1995-460907 | 19950605 (8) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1995-407207, filed on 20 Mar 1995 which is a continuation-in-part of Ser. No. US 1993-141893, filed on 26 Oct 1993, now | |

patented,
Pat. No. US 5489519, issued on 6 Feb 1996 which is a continuation-in-part of Ser. No. US 1993-29340, filed on 8 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-966923, filed on 27 Oct 1992, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: LaGuyader, John L.
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Steeg, Carol Mlernicki; Kara, Catherine J.; DeConti, Jr., Giulio A.

NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 4215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 10 USPATFULL

TI Methods for identifying multidrug resistant tumor cells

AB A novel protein associated with **multidrug resistance** in living cells and capable of conferring **multidrug resistance** on a cell is disclosed. Nucleic acids encoding the novel **multidrug resistance** protein are also disclosed. Transformant cell lines which express the nucleic acid

the encoding the novel protein are also disclosed. Antibodies which bind

novel **multidrug resistance** protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:33784 USPATFULL

TITLE: Methods for identifying multidrug resistant tumor cells

INVENTOR(S): Deeley, Roger G., Kingston, Canada
Cole, Susan P. C., Kingston, Canada

PATENT ASSIGNEE(S): Queen's University at Kingston, Kingston, Canada
(non-U.S. corporation)

| | NUMBER | DATE |
|-----------------------|---|--------------|
| PATENT INFORMATION: | US 5882875 | 19990316 |
| APPLICATION INFO.: | US 1995-462109 | 19950605 (8) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1995-407207, filed on 20 Mar 1995 which is a continuation-in-part of Ser. No. US 1993-141893, filed on 26 Oct 1993, now | |

patented,

Pat. No. US 5489519, issued on 6 Feb 1996 which is a continuation-in-part of Ser. No. US 1993-29340, filed on 8 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-966923, filed on 27 Oct 1992, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Huff, Sheela
ASSISTANT EXAMINER: Reeves, Julie E
LEGAL REPRESENTATIVE: Steeg, Carol Miernicki; Kara, Catherine J.; DeConti, Jr., Giulio A.

NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 4149

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 10 USPATFULL

TI Isolated nucleic acid molecules encoding **multidrug resistance** proteins

AB A novel protein associated with **multidrug resistance** in living cells and capable of conferring **multidrug resistance** on a cell is disclosed. Nucleic acids encoding the novel **multidrug resistance** protein are also disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Antibodies which bind

the

novel **multidrug resistance** protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:68805 USPATFULL

TITLE: Isolated nucleic acid molecules encoding **multidrug resistance** proteins

INVENTOR(S): Deeley, Roger G., Kingston, Canada
Cole, Susan P.C., Kingston, Canada

PATENT ASSIGNEE(S): Queen's University at Kingston, Kingston, Canada
(non-U.S. corporation)

| | NUMBER | DATE |
|--|---|--------------|
| PATENT INFORMATION: | US 5766880 | 19980616 |
| APPLICATION INFO.: | US 1995-463092 | 19950605 (8) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1995-407207, filed on 20 Mar 1995 which is a continuation-in-part of Ser. No. US 1993-141893, filed on 26 Oct 1993, now patented, | |
| | Pat. No. US 5489519, issued on 6 Feb 1996 which is a continuation-in-part of Ser. No. US 1993-29340, filed on 8 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-966923, filed on 27 Oct 1992, now abandoned | |
| DOCUMENT TYPE: | Utility | |
| PRIMARY EXAMINER: | Elliott, George C. | |
| ASSISTANT EXAMINER: | Schwarteman, Robert | |
| LEGAL REPRESENTATIVE: | Steeg, Carol Miernicki; Kara, Catherine J.; DeConti, Jr., Giulio A. | |
| NUMBER OF CLAIMS: | 16 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 30 Drawing Figure(s); 21 Drawing Page(s) | |
| LINE COUNT: | 3632 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | |

L6 ANSWER 7 OF 10 USPATFULL
 TI **Multidrug resistance** protein
 AB A novel protein associated with **multidrug resistance** in living cells and capable of conferring **multidrug resistance** on a cell is disclosed and nucleic acids encoding the novel isoforms are disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Further, diagnostic and treatment methods using the novel protein, nucleic acids and cell lines are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 ACCESSION NUMBER: 96:11065 USPATFULL
 TITLE: **Multidrug resistance** protein
 INVENTOR(S): Deeley, Roger G., Kingston, Canada
 Cole, Susan P. C., Kingston, Canada
 PATENT ASSIGNEE(S): Queen's University at Kingston, Kingston, Canada
 (non-U.S. corporation)

| | NUMBER | DATE |
|--|--|--------------|
| PATENT INFORMATION: | US 5489519 | 19960206 |
| APPLICATION INFO.: | US 1993-141893 | 19931026 (3) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1993-29340, filed on 8 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-966923, filed on 27 Oct 1992, now abandoned | |
| DOCUMENT TYPE: | Utility | |
| PRIMARY EXAMINER: | Furman, Keith C. | |
| LEGAL REPRESENTATIVE: | Lahive & Cockfield | |
| NUMBER OF CLAIMS: | 33 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 22 Drawing Figure(s); 17 Drawing Page(s) | |
| LINE COUNT: | 2919 | |
| CAS INDEXING IS AVAILABLE FOR THIS PATENT. | | |

L6 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2001 ACS
 TI Identification of **P-40** as **Annexin I** and its role in **multidrug resistance**
 AB The invention identifies **P-40** as **Annexin I**, a member of a large family of calcium-dependent phospholipid binding

proteins implicated in intracellular membrane vascular trafficking and exocytosis process. The overexpression of **P-40** alone or together with P-glycoprotein (P-gp) or the **multidrug resistance** assocd. protein (MRP) in MDR cell lines has been previously reported, but this invention is the first to show the role of **Annexin I (P-40)** overexpression in the resistance of tumor cells to Taxol and adriamycin, the identification of its gene as a member of the MDR gene family, and the existence of an **Annexin-based multidrug resistance** pathway. Also provided is a **method** of reducing **Annexin-based** MDR in a cell or animal, comprising the step of administering a therapeutically effective amt. of a pharmaceutical compn. according to

the

invention.

ACCESSION NUMBER: 1999:299504 HCAPLUS
DOCUMENT NUMBER: 130:308198
TITLE: Identification of **P-40** as **Annexin I** and its role in **multidrug resistance**
INVENTOR(S): Georges, Elias; Wang, Ying
PATENT ASSIGNEE(S): McGill University, Can.
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|--|----------|-----------------|----------|
| WO 9921980 | A1 | 19990506 | WO 1998-CA992 | 19981026 |
| W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2219299 | AA | 19990424 | CA 1997-2219299 | 19971024 |
| AU 9896174 | A1 | 19990517 | AU 1998-96174 | 19981026 |
| EP 1025225 | A1 | 20000809 | EP 1998-949842 | 19981026 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | |

PRIORITY APPLN. INFO.: CA 1997-2219299 A 19971024
WO 1998-CA992 W 19981026

REFERENCE COUNT: 6
REFERENCE(S):
(2) Biogen Nv; WO 8604094 A 1986 HCAPLUS
(3) Carollo, M; ONCOLOGY RESEARCH 1998, V10(5), P245 HCAPLUS
(4) Cole, S; BRITISH JOURNAL OF CANCER 1992, V65(4), P498 HCAPLUS
(5) Horseman, N; GENERAL AND COMPARATIVE ENDOCRINOLOGY 1992, V85(3), P405 HCAPLUS
(6) Wang, Y; BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 1997, V236(2), P483 HCAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 10 BIOTECHDS COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Modulating or assessing **multidrug-resistance** related to **annexin** protein;
recombinant **annexin**, DNA probe and antisense DNA, useful for the reversal of cancer therapy-induced **multidrug-resistance** and for drug screening for e.g. fungicide

AN 1999-09800 BIOTECHDS
AB An isolated DNA sequence (I) encoding an **annexin** family member (II), i.e. a member of the **multidrug-resistance** family, for assessing or modulating MDR in a cell is new. Also claimed are: detection and assessment of **annexin**-based MDR using a DNA probe; kits for this **method**; a recombinant vector, preferably plasmid pCDNA3/P-40 or plasmid pC1N4P-40, for modulating **annexin**-based MDR in a cell; host cells e.g. mammal, parasitic, fungal cells containing this vector; a drug screening **method** to identify agents that affect **annexin**-based MDR; a **method** of reducing **annexin**-based MDR by administering a nucleic acid dominant negative mutant of **annexin**, **annexin**-specific antibody or a peptide or small molecule; a pharmaceutical composition for reducing MDR comprising an **annexin**-based MDR-modulating compound; and methods for diagnosing the presence of, or predisposition to, **annexin**-based MDR in a patient or pathogen. Antisense sequences to (I) are useful for preventing MDR in animals, particularly in conjunction with cancer therapy. (II) is useful

as a target for identifying e.g. fungicides and increasing (II) expression in plants to develop specific resistances. (62pp)

ACCESSION NUMBER: 1999-09800 BIOTECHDS

TITLE: Modulating or assessing **multidrug-resistance** related to **annexin** protein; recombinant **annexin**, DNA probe and antisense DNA, useful for the reversal of cancer therapy-induced **multidrug-resistance** and for drug screening for e.g. fungicide

AUTHOR: Georges E; Wang Y
PATENT ASSIGNEE: Univ.McGill
LOCATION: Montreal, Quebec, Canada.
PATENT INFO: WO 9921980 6 May 1999
APPLICATION INFO: WO 1998-CA992 26 Oct 1998
PRIORITY INFO: CA 1997-2219299 24 Oct 1997
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: WPI: 1999-337419 [28]

L6 ANSWER 10 OF 10 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

TI Modulating or assessing **multidrug resistance** related to **annexin** proteins.

AN 1999-337419 [28] WPIDS

AB WO 9921980 A UPAB: 19990719

NOVELTY - Isolated nucleic acid (I) encoding an **annexin** family member (II), i.e. a member of the MDR (**multidrug resistance**) gene family, for assessing or modulating MDR in a cell, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a **method** for detecting and assessing **annexin**-based MDR by treating test sample with an oligonucleotide (ON) containing 10-50 nucleotides (nt) that hybridize specifically to RNA and/or DNA encoding an **annexin**, ON being complementary to a sequence of at least 10 consecutive nt from the sequences for annexins I to IX, and detecting any hybrids formed;
- (2) kits for this **method**;
- (3) recombinant vector for modulating, inhibiting and/or increasing **annexin**-based MDR in a cell, containing (I) linked to a promoter;
- (4) cells containing this vector;
- (5) a **method** for identifying compounds that affect **annexin**-based MDR by incubating with test compound in presence or absence of a drug and assessing any effect of the test compound on resistance to the drug;

(6) a method of reducing **annexin**-based MDR by administering a nucleic acid, (dominant negative) mutant of **annexin**, antibody **annexin**, peptide or small molecule;
 (7) pharmaceutical composition for reducing MDR comprising **annexin**-based MDR-affecting compound and a carrier; and
 (8) methods for diagnosing presence of, or predisposition to, **annexin**-based MDR in a patient or pathogen.

ACTIVITY - Antitumor; antifungal.

MECHANISM OF ACTION - None given.

USE - Antisense sequences from (I), or any other agent that inhibits (II), are used to prevent MDR in animals, particularly in conjunction with cancer treatment. Detecting levels of (II), or related RNA, is used to detect cancer (or pathogens) with MDR, or susceptibility. (II) can also be used as a target for identifying therapeutic agents, e.g. antifungal agents, and increasing (II) expression in plants may be used to develop specific resistance.

Dwg.0/9

ACCESSION NUMBER: 1999-337419 [28] WPIDS
 DOC. NO. NON-CPI: N1999-252873
 DOC. NO. CPI: C1999-099183
 TITLE: Modulating or assessing **multidrug resistance** related to **annexin** proteins.
 DERWENT CLASS: B04 D16 S03
 INVENTOR(S): GEORGES, E; WANG, Y
 PATENT ASSIGNEE(S): (UYMC-N) UNIV MCGILL; (GEOR-I) GEORGES E; (WANG-I) WANG Y
 COUNTRY COUNT: 83
 PATENT INFORMATION:

| PATENT NO | KIND | DATE | WEEK | LA | PG |
|--|------|----------|-----------|----|----|
| WO 9921980 | A1 | 19990506 | (199928)* | EN | 62 |
| RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW | | | | | |
| W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW | | | | | |
| AU 9896174 | A | 19990517 | (199939) | | |
| CA 2219299 | A1 | 19990424 | (199940) | EN | |
| EP 1025225 | A1 | 20000809 | (200039) | EN | |
| R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE | | | | | |

APPLICATION DETAILS:

| PATENT NO | KIND | APPLICATION | DATE |
|------------|------|-----------------|----------|
| WO 9921980 | A1 | WO 1998-CA992 | 19981026 |
| AU 9896174 | A | AU 1998-96174 | 19981026 |
| CA 2219299 | A1 | CA 1997-2219299 | 19971024 |
| EP 1025225 | A1 | EP 1998-949842 | 19981026 |
| | | WO 1998-CA992 | 19981026 |

FILING DETAILS:

| PATENT NO | KIND | PATENT NO |
|------------|-------------|------------|
| AU 9896174 | A Based on | WO 9921980 |
| EP 1025225 | A1 Based on | WO 9921980 |

PRIORITY APPLN. INFO: CA 1997-2219299 19971024

=> e georges, e/au

| | | |
|-----|-------|------------------------|
| E1 | 1 | GEORGES YVES MARTHE/AU |
| E2 | 1 | GEORGES Z/AU |
| E3 | 0 --> | GEORGES, E/AU |
| E4 | 5 | GEORGESC C/AU |
| E5 | 4 | GEORGESC D/AU |
| E6 | 2 | GEORGESC II/AU |
| E7 | 3 | GEORGESC M/AU |
| E8 | 2 | GEORGESC S/AU |
| E9 | 1 | GEORGESC V/AU |
| E10 | 1 | GEORGESCA L/AU |
| E11 | 1 | GEORGESCALUD D/AU |
| E12 | 5 | GEORGESCAUD D/AU |

=> e wang, Y/au

| | | |
|-----|-------|------------------|
| E1 | 1 | WANG ZXINGTAI/AU |
| E2 | 2 | WANG ZYX/AU |
| E3 | 0 --> | WANG, Y/AU |
| E4 | 1 | WANG1 Y/AU |
| E5 | 1 | WANGA A P/AU |
| E6 | 1 | WANGA C/AU |
| E7 | 1 | WANGA C C/AU |
| E8 | 1 | WANGA D/AU |
| E9 | 1 | WANGA D B/AU |
| E10 | 1 | WANGA G/AU |
| E11 | 1 | WANGA G J/AU |
| E12 | 1 | WANGA K C/AU |

Trying 3106016892...Open

Welcome to STN International! Enter x:x
 LOGINID:sssptal653hxp
 PASSWORD:
 TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files
 NEWS 3 Feb 06 Engineering Information Encompass files have new names
 NEWS 4 Feb 16 TOXLINE no longer being updated
 NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
 NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA

NEWS EXPRESS April 18 CURRENT WINDOWS VERSION IS V6.0,
 CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
 AND CURRENT DISCOVER FILE IS DATED 04/06

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:29:23 ON 27 APR 2001

=> file medline, biosis, dgene, uspat, hcaplus, wpids, biotechds, frosti, fsta, jicst, japio

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 0.30 | 0.30 |

FILE 'MEDLINE' ENTERED AT 13:30:11 ON 27 APR 2001

FILE 'BIOSIS' ENTERED AT 13:30:11 ON 27 APR 2001
 COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'DGENE' ENTERED AT 13:30:11 ON 27 APR 2001
 COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'USPATFULL' ENTERED AT 13:30:11 ON 27 APR 2001
 CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'HCAPLUS' ENTERED AT 13:30:11 ON 27 APR 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 13:30:11 ON 27 APR 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'BIOTECHDS' ENTERED AT 13:30:11 ON 27 APR 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'FROSTI' ENTERED AT 13:30:11 ON 27 APR 2001
COPYRIGHT (C) 2001 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 13:30:11 ON 27 APR 2001
COPYRIGHT (C) 2001 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 13:30:11 ON 27 APR 2001
COPYRIGHT (C) 2001 Japan Science and Technology Corporation (JST)

FILE 'JAPIO' ENTERED AT 13:30:11 ON 27 APR 2001
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

=> multidrug resisitance

MULTIDRUG IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s MDR or multidrug resistance

L1 28120 MDR OR MULTIDRUG RESISTANCE

=> s p-40

L2 10653 P-40

=> s mcf-7 cells

L3 9068 MCF-7 CELLS

=> s l3 and l2

L4 32 L3 AND L2

=> s l1 and l4

L5 1 L1 AND L4

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 1 USPATFULL

TI Inadone and tetralone compounds for inhibiting cell proliferation

AB A new family of inadone and tetralone tubulin-binding compounds (TBs)

is

disclosed. Unlike classical TBs, which inhibit mitosis among affected
dividing cells, the TBs of the invention possess two unique properties:
(1) they induce apoptosis among stationary phase (non-dividing)
malignant cells, yet do not impair the viability of normal
nonproliferating cells; and, (2) they affect cells which have acquired
MDR more powerfully than they affect cells without **MDR**

. Thus, the TBS of the invention provide means to target malignant cells
for chemotherapy, even after previous therapies e failed, without affecting normal cells and tissues in the host.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:171034 USPATFULL

TITLE: Inadone and tetralone compounds for inhibiting cell proliferation

INVENTOR(S): Carson, Dennis A., Del Mar, CA, United States
Shih, Hsien C., San Diego, CA, United States
Cottam, Howard B., Fallbrook, CA, United States
Leoni, Lorenzo, San Diego, CA, United States

PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

| | NUMBER | DATE |
|-----------------------|--|--------------|
| PATENT INFORMATION: | US 6162810 | 20001219 |
| APPLICATION INFO.: | US 1998-148576 | 19980904 (9) |
| DOCUMENT TYPE: | Utility | |
| PRIMARY EXAMINER: | McKane, Joseph K. | |
| ASSISTANT EXAMINER: | Solola, Taofiq A. | |
| LEGAL REPRESENTATIVE: | Townsend and Townsend and Crew, LLP | |
| NUMBER OF CLAIMS: | 42 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 6 Drawing Figure(s); 5 Drawing Page(s) | |
| LINE COUNT: | 1308 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 13:29:23 ON 27 APR 2001)

FILE 'MEDLINE, BIOSIS, DGENE, USPATFULL, HCAPLUS, WPIDS, BIOTECHDS, FROSTI, FSTA, JICST-EPLUS, JAPIO' ENTERED AT 13:30:11 ON 27 APR 2001

L1 28120 S MDR OR MULTIDRUG RESISTANCE
L2 10653 S P-40
L3 9068 S MCF-7 CELLS
L4 32 S L3 AND L2
L5 1 S L1 AND L4

=> s 14 and taxol

L6 1 L4 AND TAXOL

=> s 14 and adriamycin

L7 5 L4 AND ADRIAMYCIN

=> s 16 and 17

L8 1 L6 AND L7

=> s 18 and 15

L9 1 L8 AND L5

=> d 17 ti abs ibib tot

L7 ANSWER 1 OF 5 USPATFULL

TI Inadone and tetralone compounds for inhibiting cell proliferation
AB A new family of adone and tetralone tubulin-binding compounds (TBs)
is disclosed. Unlike classical TBs, which inhibit mitosis among affected
dividing cells, the TBs of the invention possess two unique properties:
(1) they induce apoptosis among stationary phase (non-dividing)
malignant cells, yet do not impair the viability of normal
nonproliferating cells; and, (2) they affect cells which have acquired
MDR more powerfully than they affect cells without MDR. Thus, the TBs
of the invention provide means to target malignant cells for chemotherapy,
even after previous therapies have failed, without affecting normal
cells and tissues in the host.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:171034 USPATFULL
TITLE: Inadone and tetralone compounds for inhibiting cell
proliferation
INVENTOR(S): Carson, Dennis A., Del Mar, CA, United States
Shih, Hsien C., San Diego, CA, United States
Cottam, Howard B., Fallbrook, CA, United States
Leoni, Lorenzo, San Diego, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland,
CA, United States (U.S. corporation)

| | NUMBER | DATE |
|-----------------------|--|--------------|
| PATENT INFORMATION: | US 6162810 | 20001219 |
| APPLICATION INFO.: | US 1998-148576 | 19980904 (9) |
| DOCUMENT TYPE: | Utility | |
| PRIMARY EXAMINER: | McKane, Joseph K. | |
| ASSISTANT EXAMINER: | Solola, Taofiq A. | |
| LEGAL REPRESENTATIVE: | Townsend and Townsend and Crew, LLP | |
| NUMBER OF CLAIMS: | 42 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 6 Drawing Figure(s); 5 Drawing Page(s) | |
| LINE COUNT: | 1308 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 5 USPATFULL

TI Methods of use of a ductal carcinoma antigen
AB Monoclonal antibodies to adenocarcinoma cells, and, in particular,
breast carcinoma cells, are produced by a hybridoma formed by fusing
mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies
are capable of shrinking solid tumors associated with human breast. The
monoclonal antibodies identify an antigen associated with carcinomas of
ductal lineage. The monoclonal antibodies, specifically, F36/22
monoclonal antibodies, can be used diagnostically and therapeutically.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:21919 USPATFULL
TITLE: Methods of use of a ductal carcinoma antigen
INVENTOR(S): Chu, Tsann Ming, Williamsville, NY, United States
Papsidero, Lawrence D., Orchard Park, NY, United
States
PATENT ASSIGNEE(S): Health Research, Inc., Buffalo, NY, United States
(U.S. corporation)

| | NUMBER | DATE |
|---------------------|----------------|--------------|
| PATENT INFORMATION: | US 5871936 | 19990216 |
| APPLICATION INFO.: | US 1997-979691 | 19971126 (8) |

RELATED APPLN. INFO.: Division of Ser. No. US 1996-733631, filed on 17 Oct 1996 which is a division of Ser. No. US 1989-408817, filed on 18 Sep 1989, now patented, Pat. No. US

5652114

which is a division of Ser. No. US 1985-775062, filed on 11 Sep 1985, now patented, Pat. No. US 4939240

which

is a continuation-in-part of Ser. No. US 1983-472222, filed on 4 Mar 1983, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Ungar, Susan
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2577

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 5 USPATFULL

TI Purified ductal carcinoma antigen

AB Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies

are

capable of shrinking solid tumors associated with human breast. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:101735 USPATFULL
TITLE: Purified ductal carcinoma antigen
INVENTOR(S): Chu, Tsann Ming, Williamsville, NY, United States
Papsidero, Lawrence D., Orchard Park, NY, United States
States
PATENT ASSIGNEE(S): Health Research, Inc., Buffalo, NY, United States
(U.S. corporation)

| | NUMBER | DATE |
|-----------------------|---|--------------|
| PATENT INFORMATION: | US 5798445 | 19980825 |
| APPLICATION INFO.: | US 1996-733631 | 19961017 (8) |
| RELATED APPLN. INFO.: | Division of Ser. No. US 1989-408817, filed on 18 Sep 1989, now patented, Pat. No. US 5652114 which is a division of Ser. No. US 1985-755062, filed on 11 Sep 1985, now patented, Pat. No. US 4939240 which is a continuation-in-part of Ser. No. US 1983-472222, filed on 4 Mar 1983, now abandoned | |
| DOCUMENT TYPE: | Utility | |
| PRIMARY EXAMINER: | Feisee, Lisa | |
| ASSISTANT EXAMINER: | Ungar, Susan | |
| LEGAL REPRESENTATIVE: | Pennie & Edmonds LLP | |
| NUMBER OF CLAIMS: | 3 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 4 Drawing Figure(s); 4 Drawing Page(s) | |
| LINE COUNT: | 2571 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 5 USPATFULL

TI Diagnostic immunoassay methods using monoclonal antibody F36/22 which is specific for human breast carcinoma cells

AB Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are capable of shrinking solid human breast tumors xenografted in nude mice. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:66006 USPATFULL

TITLE: Diagnostic immunoassay methods using monoclonal antibody F36/22 which is specific for human breast carcinoma cells

INVENTOR(S): Chu, Tsann Ming, Williamsville, NY, United States
Papsidero, Lawrence D., Orchard Park, NY, United States

PATENT ASSIGNEE(S): Croghan, Gary A., Rochester, NY, United States
Health Research Inc., Buffalo, NY, United States (U.S. corporation)

| | NUMBER | DATE |
|-----------------------|---|--------------|
| PATENT INFORMATION: | US 5652114 | 19970729 |
| APPLICATION INFO.: | US 1989-408817 | 19890918 (7) |
| RELATED APPLN. INFO.: | Continuation of Ser. No. US 1985-775062, filed on 11 Sep 1985, now patented, Pat. No. US 4939240 which is a continuation-in-part of Ser. No. US 1983-472222, filed on 4 Mar 1983, now abandoned | |
| DOCUMENT TYPE: | Utility | |
| PRIMARY EXAMINER: | Hutzell, Paula K. | |
| LEGAL REPRESENTATIVE: | Pennie & Edmonds | |
| NUMBER OF CLAIMS: | 17 | |
| EXEMPLARY CLAIM: | 1 | |
| NUMBER OF DRAWINGS: | 4 Drawing Figure(s); 4 Drawing Page(s) | |
| LINE COUNT: | 2616 | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 5 USPATFULL

TI Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy

AB Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are

capable of shrinking solid tumors associated with human breast. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 90:52969 USPATFULL

TITLE: Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy

INVENTOR(S): Chu, Tsann M., Williamsville, NY, United States
Papsidero, Lawrence D., Orchard Park, NY, United States

States
PATENT ASSIGNEE(S): Health Research, Inc., Buffalo, NY, United States
(U.S. corporation)

| NUMBER | DATE |
|--------|------|
|--------|------|

PATENT INFORMATION: US 4939240 19900703
APPLICATION INFO.: S 1985-775062 19850911 (6)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1983-472222, filed
on 4 Mar 1983, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Moskowitz, Margaret
ASSISTANT EXAMINER: Cheney, Kay E.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2486
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 13:29:23 ON 27 APR 2001)

FILE 'MEDLINE, BIOSIS, DGENE, USPATFULL, HCAPLUS, WPIDS, BIOTECHDS,
FROSTI, FSTA, JICST-EPLUS, JAPIO' ENTERED AT 13:30:11 ON 27 APR 2001

L1 28120 S MDR OR MULTIDRUG RESISTANCE
L2 10653 S P-40
L3 9068 S MCF-7 CELLS
L4 32 S L3 AND L2
L5 1 S L1 AND L4
L6 1 S L4 AND TAXOL
L7 5 S L4 AND ADRIAMYCIN
L8 1 S L6 AND L7
L9 1 S L8 AND L5

=> d 19 ti abs ibib tot

L9 ANSWER 1 OF 1 USPATFULL
TI Inadone and tetralone compounds for inhibiting cell proliferation
AB A new family of inadone and tetralone tubulin-binding compounds (TBs)
is disclosed. Unlike classical TBs, which inhibit mitosis among affected
dividing cells, the TBs of the invention possess two unique properties:
(1) they induce apoptosis among stationary phase (non-dividing)
malignant cells, yet do not impair the viability of normal
nonproliferating cells; and, (2) they affect cells which have acquired
MDR more powerfully than they affect cells without **MDR**
. Thus, the TBs of the invention provide means to target malignant
cells
for chemotherapy, even after previous therapies have failed, without
affecting normal cells and tissues in the host.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:171034 USPATFULL
TITLE: Inadone and tetralone compounds for inhibiting cell
proliferation
INVENTOR(S): Carson, Dennis A., Del Mar, CA, United States
Shih, Hsien C., San Diego, CA, United States
Cottam, Howard B., Fallbrook, CA, United States
Leoni, Lorenzo, San Diego, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland,
CA, United States (U.S. corporation)

NUMBER DATE

PATENT INFORMATION: US 6162810 20001219
APPLICATION INFO.: US 1998-148576 19980904 (9)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: McKane, Joseph K.
ASSISTANT EXAMINER: Solola, Taofiq A.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew, LLP
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1308
CAS INDEXING IS AVAILABLE FOR THIS PATENT.